Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
PROCEPT BioRobotics
PRCT
PROCEPT BioRobotics
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
06 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$51.00
18.5% undervalued
intrinsic discount
10 Aug
US$41.59
Loading
1Y
-35.7%
7D
8.3%
Author's Valuation
US$51.0
18.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$51.0
18.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-105m
554m
2019
2021
2023
2025
2027
2028
Revenue US$554.3m
Earnings US$68.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
20.20%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.55%
Calculation
US$68.43m
Earnings '28
x
62.11x
PE Ratio '28
=
US$4.25b
Market Cap '28
US$4.25b
Market Cap '28
/
67.47m
No. shares '28
=
US$62.99
Share Price '28
US$62.99
Share Price '28
Discounted to 2025 @ 7.54% p.a.
=
US$50.64
Fair Value '25
